Search

Your search keyword '"Zabana, Y."' showing total 104 results
Start Over Author "Zabana, Y." Search Limiters Full Text
104 results on '"Zabana, Y."'

1. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

Author

Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, Gisbert JP, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, Lucendo AJ, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de-Acosta M, Sicilia B, Barrio J, Pérez JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, de Zarate JO, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu, [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa, and Universidad de Sevilla. Departamento de Medicina

Subjects
index, Pronòstic mèdic, Risk factors in diseases, COVID-19 (Malaltia), Article, Inflammatory bowel disease, Comorbiditat, inflammatory bowel disease, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity [PUBLIC HEALTH], Factors de risc en les malalties, SARS-CoV-2, COVID-19, determinants, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Prognosis, enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES], infection, epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad [SALUD PÚBLICA], Medicine, Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES], Intestins - Inflamació
Abstract

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged >= 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having >= 2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. This study is funded by the Carlos III Health Institute (COV20/00227: Co-IP Dra. Maria Esteve and Dra. Yamile Zabana), FEDER (Fondo Europeo de Desarrollo Regional) and supported by GETECCU. The ENEIDA Registry of GETECCU is supported by Takeda, Pfizer, Galapagos, AbbVie and Biogen.

Published
2022

2. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study

Author

Mañosa, M., Calafat, M., de Francisco, R., García, C., Casanova, M. J., Huelín, P., Calvo, M., Tosca, J., Fernández‐Salazar, L., Arajol, C., Zabana, Y., Bastida, G., Hinojosa, J., Márquez, L., Barreiro‐de‐Acosta, M., Calvet, X., Monfort, D., Gómez‐Garcia, M. R., Rodríguez, E., Huguet, J. M., Rojas‐Feria, M., Hervias, D., Atienza, R., Busquets, D., Zapata, E., Dueñas, C., Charro, M., Martínez‐Cerezo, F. J., Plaza, R., Vázquez, J. M., Gisbert, J. P., Cañete, F., Cabré, E., Domènech, E., Arajol, Clàudia, Atienza, Ramón, Barreiro‐de‐Acosta, Manuel, Bastida, Guillermo, Busquets, David, Calafat, Margalida, Calvet, Xavier, Calvo, Marta, Cabré, Eduard, Cañete, Fiorella, Casanova, Mª José, Charro, Mara, Dueñas, Carmen, Domènech, Eugeni, de Francisco, Ruth, Fernández‐Salazar, Luis, García, Carmen, Gómez‐Garcia, María Rosario, Hervias, Daniel, Hinojosa, Joaquín, Huelín, Patricia, Huguet, José Mª, Mañosa, Míriam, Márquez, Lucía, Martínez‐Cerezo, Francisco J., Monfort, David, Gisbert, Javier P., Plaza, Rocío, Rodríguez, Esther, Rojas‐Feria, María, Tosca, Joan, Vázquez, Juan M., Zabana, Yamile, and Zapata, Eva

Published
2018
Full Text
View/download PDF

3. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

Author

Iglesias, RF, Silva, MSP, Marin, S, Casanova, MJ, Manosa, M, Gonzalez-Munoza, C, de Francisco, R, Caballol, B, Arias, L, Piqueras, M, Zabana, Y, Rivero, M, Calvet, X, Mesonero, F, Trastoy, PV, Nistal, RB, Perosanz, RG, Vega, P, Vivo, MG, Iborra, M, Marquez, LJ, Madero, L, Rodriguez-Lago, I, Gonzalez, MR, Vera, I, Diaz, AP, Vela, M, Torrealba, L, Van Domselaar, M, Iglesias, E, Gisbert, JP, Calafat, M, Garcia-Planella, E, Perez-Martinez, I, Ricart, E, Sicilia, B, Mena, R, Nieto, L, Domenech, E, and Acosta, MBD

Published
2022

4. Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU)

Author

Rey I, Suarez C, Luque A, Caballol B, Soutullo C, Bravo A, Castano A, Gros B, Bernal L, Lois M, Galan H, Canete F, Castro B, Galindo P, Munoza C, El Hajra I, Montiel P, Abreu I, Mesonero F, Vivo M, Peries L, Arranz E, Abril C, Jimenez I, Baltar R, Vicuna M, Moreno N, Brunet E, de Celix C, Fajardo I, Cruz N, Feria M, Clotet A, Gimeno M, Zabana Y, Ferrer C, Lago I, and de Acosta M

Published
2022

6. Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)

Author

Vivo, MG, Ferreruela, MU, Senosiain, BC, Perez-Martinez, I, Barrio, J, Prado, LC, Oliva, BC, Roman, VP, Cano, MP, Moranta, FR, Gonzalez, MJC, Ramos, L, Iborra, M, Marin, CT, Barreiro-de Acosta, M, Poyatos, RHL, Jorquera, BO, Fernandez, LB, Zabana, Y, Lopez-Garcia, A, Riestra, S, Vega-Villaamil, P, Montoro, M, Gisbert, JP, Nos, P, Gonzalez, GER, Silva, MP, Gutierrez-Casbas, A, Domenech, E, and Marquez, L

Published
2022

7. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

Author

Barreiro-de Acosta, M, Riestra, S, Calafat, M, Soto, MP, Calvo, M, Rodriguez, ES, Caballol, B, Vela, M, Rivero, M, Munoz, F, de Castro, L, Calvet, X, Garcia-Alonso, FJ, Fornals, AU, Ferreiro-Iglesias, R, Gonzalez-Munoza, C, Chaparro, M, Bujanda, L, Sicilia, B, Alfambra, E, Rodriguez, A, Fernandez, RP, Rodriguez, C, Almela, P, Arguelles, F, Busquets, D, Tamarit-Sebastian, S, Castro, CR, Jimenez, L, Marin-Jimenez, I, Alcaide, N, Fernandez-Salgado, E, Iglesias, A, Ponferrada, A, Pajares, R, Roncero, O, Morales-Alvarado, VJ, Ispizua-Madariaga, N, Sainz, E, Merino, O, Marquez-Mosquera, L, Garcia-Sepulcre, M, Elorza, A, Estrecha, S, Suris, G, Van Domselaar, M, Brotons, A, de Francisco, R, Canete, F, Iglesias, E, Vera, MI, Mesonero, F, Lorente, R, Zabana, Y, Cabriada, JL, Domenech, E, Rodriguez-Lago, I, and Registry, ESGFTE

Subjects
surgery, Crohn's disease, enterocutaneous fistula, fistula
Abstract

Background and aims Crohn's disease [CD] can develop penetrating complications at any time during the disease course. Enterocutaneous fistulae [ECF] are disease-related complications with an important impact on quality of life. Our aim was to describe the outcomes of this complication, including its medical and/or surgical management and their temporal trends. The primary endpoint was fistula closure, defined as the absence of drainage, with no new abscess or surgery, over the preceding 6 months. Methods Clinical information from all adult patients with CD and at least one ECF-excluding perianal fistulae-were identified from the prospectively-maintained ENEIDA registry. All additional information regarding treatment for this complication was retrospectively reviewed. Results A total of 301 ECF in 286 patients [January 1970-September 2020] were analysed out of 30 088 records. These lesions were mostly located in the ileum [67%] and they had a median of one external opening [range 1-10]. After a median follow-up of 146 months (interquartile range [IQR], 69-233), 69% of patients underwent surgery. Fistula closure was achieved in 84%, mostly after surgery, and fistula recurrence was uncommon [13%]. Spontaneous and low-output fistulae were associated with higher closure rates (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.17-1.93, p = 0.001, and HR 1.49, 95% CI 1.07-2.06, p = 0.03, respectively); this was obtained more frequently with medical therapy since biologics have been available. Conclusions ECF complicating CD are rare but entail a high burden of medical and surgical resources. Closure rates are high, usually after surgery, and fistula recurrence is uncommon. A significant proportion of patients receiving medical therapy can achieve fistula closure.

Published
2022

8. Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU)

Author

Rey, IB, Suarez, CC, Luque, AM, Caballol, B, Soutullo, C, Bravo, A, Castano, A, Gros, B, Hurtado, A, Rey, TV, Galan, HA, Canete, F, Castro, B, Galindo, PP, Munoza, CG, El Hajra, I, Montiel, PM, Abreu, IA, Mesonero, F, Vivo, MG, Peries, L, Arranz, EM, Abril, C, Jimenez, IM, Baltar, R, Vicuna, M, Moreno, N, Brunet, E, Lago, IR, de Celix, CR, Fajardo, I, Cruz, N, Feria, MR, Clotet, AF, Gimeno, M, Zabana, Y, Ferrer, CS, and de Acosta, MB

Published
2022

9. Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu

Author

García, M. J., Rivero, M., Miranda-Bautista, J., Bastón-Rey, I., Mesonero, F., Leo-Carnerero, E., Casas-Deza, D., Cagigas Fernández, C., Martin-Cardona, A., El Hajra, I., Hernández-Aretxabaleta, N., Pérez-Martínez, I., Fuentes-Valenzuela, E., Jiménez, N., Rubin de Célix, C., Gutiérrez, A., Suárez Ferrer, C., Huguet, J. M., Fernández-Clotet, A., González-Vivó, M., Del Val, B., Castro-Poceiro, J., Melcarne, L., Dueñas, C., Izquierdo, M., Monfort, D., Bouhmidi, A., Ramírez de la Piscina, P., Romero, E., Molina, G., Zorrilla, J., Calvino-Suárez, C., Sánchez, E., Núñez, A., Sierra, O., Castro, B., Zabana, Y., González-Partida, I., De la Maza, S., Castaño, A., Nájera-Muñoz, R., Sánchez-Guillén, L., Riat Castro, M., Rueda, J. L., Benítez, J. M., Delgado-Guillena, P., Tardillo, C., Peña, E., Frago-Larramona, S., Rodríguez-Grau. M. C., Plaza, R., Pérez-Galindo, P., Martínez-Cadilla, J., Menchén, L., Barreiro-De Acosta, M., Sánchez-Aldehuelo, R., De la Cruz, M. D., Lamuela, L. J., Marín, I., Nieto-García, L., López San Román, A., Herrera, J. M., Chaparro, M., Gisbert, J. P., Young Group of GETECCU, [García MJ, Rivero M] Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain. [Miranda-Bautista J] Gastroenterology Department, Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), and Departamento de Medicina, Universidad Complutense, Madrid, Spain. [Bastón-Rey I] Gastroenterology Department, Hospital Universitario Clínico de Santiago, Santiago de Compostela, Spain. [Mesonero F] Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Leo-Carnerero E] Gastroenterology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Delgado-Guillena P] Gastroenterology Department, Hospital General de Granollers, Granollers, Spain, Hospital General de Granollers, [Jose Garcia, Maria] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Rivero, Montserrat] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Castro, Beatriz] Univ Cantabria, Hosp Univ Marques de Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gastroenterol Dept, Santander 37008, Spain, [Miranda-Bautista, Jose] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Menchen, Luis] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Marin, Ignacio] Univ Complutense, Hosp Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Gastroenterol Dept, Madrid 28009, Spain, [Miranda-Bautista, Jose] Univ Complutense, Dept Med, Madrid 28009, Spain, [Menchen, Luis] Univ Complutense, Dept Med, Madrid 28009, Spain, [Marin, Ignacio] Univ Complutense, Dept Med, Madrid 28009, Spain, [Baston-Rey, Iria] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Calvino-Suarez, Cristina] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Barreiro-De Acosta, Manuel] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Nieto-Garcia, Laura] Hosp Univ Clin Santiago, Gastroenterol Dept, Santiago De Compostela 15706, Spain, [Mesonero, Francisco] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Sanchez, Eugenia] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Sanchez-Aldehuelo, Ruben] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Lopez-San Roman, Antonio] Hosp Univ Ramon y Cajal, Gastroenterol Dept, Madrid 28034, Spain, [Leo-Carnerero, Eduardo] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Nunez, Andrea] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Dolores De la Cruz, Maria] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Manuel Herrera, Jose] Hosp Univ Virgen del Rocio, Gastroenterol Dept, Seville 41013, Spain, [Casas-Deza, Diego] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Sierra, Olivia] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Javier Lamuela, Luis] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Gastroenterol Dept, Zaragoza 50009, Spain, [Cagigas Fernandez, Carmen] Hosp Univ Marques de Valdecilla, Dept Gen & Digest Surg, Colorectal Unit, Santander 39008, Spain, [Martin-Cardona, Albert] Hosp Univ Mutua Terrassa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Dept, Terrassa 08221, Spain, [Zabana, Yamile] Hosp Univ Mutua Terrassa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Dept, Terrassa 08221, Spain, [El Hajra, Ismael] Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda 28220, Spain, [Gonzalez-Partida, Irene] Hosp Univ Puerta de Hierro, Gastroenterol Dept, Majadahonda 28220, Spain, [Hernandez-Aretxabaleta, Nerea] Hosp Univ Basurto, Gastroenterol Dept, Bilbao 48013, Spain, [De la Maza, Saioa] Hosp Univ Basurto, Gastroenterol Dept, Bilbao 48013, Spain, [Perez-Martinez, Isabel] Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA 33, Dept Gastroenterol, Oviedo 33011, Spain, [Castano, Andres] Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias ISPA 33, Dept Gastroenterol, Oviedo 33011, Spain, [Fuentes-Valenzuela, Esteban] Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid 47012, Spain, [Najera-Munoz, Rodrigo] Hosp Univ Rio Hortega, Gastroenterol Dept, Valladolid 47012, Spain, [Jimenez, Nuria] Hosp Gen Univ Elche, Gastroenterol Dept, Alicante 03203, Spain, [Rubin de Celix, Cristina] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Castro, Micaela Riat] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Chaparro, Maria] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Gisbert, Javier P.] Univ Autonoma Madrid UAM, Gastroenterol Dept, Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IIS IP,Ctr Invest, Madrid 28006, Spain, [Gutierrez, Ana] Hosp Gen Alicante, Gastroenterol Dept, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Alicante 03010, Spain, [Suarez Ferrer, Cristina] Hosp Univ La Paz, Gastroenterol Dept, Madrid 28046, Spain, [Luis Rueda, Jose] Hosp Univ La Paz, Gastroenterol Dept, Madrid 28046, Spain, [Maria Huguet, Jose] Hosp Gen Univ Valencia, Gastroenterol Dept, Valencia 46014, Spain, [Fernandez-Clotet, Agnes] Hosp Clin Barcelona, Gastroenterol Dept, Barcelona 08036, Spain, [Gonzalez-Vivo, Maria] Hosp del Mar, Gastroenterol Dept, Barcelona 08003, Spain, [Del Val, Blanca] Hosp Rafael Mendez, Gastroenterol Dept, Lorca 30817, Spain, [Castro-Poceiro, Jesus] Hosp St Joan Despi Moises Broggi, Gastroenterol Dept, Barcelona 08970, Spain, [Melcarne, Luigi] Hosp Univ Parc Tauli, Gastroenterol Dept, Sabadell, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona 08208, Spain, [Duenas, Carmen] Hosp Univ Caceres, Gastroenterol Dept, Caceres 10003, Spain, [Izquierdo, Marta] Hosp Univ Cabuenes, Gastroenterol Dept, Gijon 33203, Spain, [Monfort, David] Consorcio Sanitario Terrasa, Gastroenterol Dept, Barcelona 08227, Spain, [Bouhmidi, Abdel] Hosp Santa Barbara, Gastroenterol Dept, Puertollano 13500, Spain, [Ramirez De la Piscina, Patricia] Hosp Univ Vitoria Gasteiz, Gastroenterol Dept, Vitoria 01002, Spain, [Romero, Eva] Hosp Clin Univ Valencia, Gastroenterol Dept, Valencia 46010, Spain, [Molina, Gema] Hosp Arquitecto Marcide, Gastroenterol Dept, Ferrol 15405, Spain, [Zorrilla, Jaime] Hosp Univ Gregorio Maranon, Dept Colorectal & Gastrointestinal Surg, Madrid 28009, Spain, [Sanchez-Guillen, Luis] Hosp Gen Univ Elche, Dept Colorectal & Gastrointestinal Surg, Alicante 03203, Spain, [Manuel Benitez, Jose] Hosp Reina Sofia, Gastroenterol Dept, IMIBIC, Cordoba 14004, Spain, [Delgado-Guillena, Pedro] Hosp Gen Granollers, Gastroenterol Dept, Granollers 08042, Spain, [Tardillo, Carlos] Hosp Nuestra Sanora de la Candelaria, Gastroenterol Dept, Tenerife 38010, Spain, [Pena, Elena] Hosp Royo Villanova, Gastroenterol Dept, Zaragoza 50007, Spain, [Frago-Larramona, Santiago] Complejo Hosp Soria, Gastroenterol Dept, Soria 42005, Spain, [Carmen Rodriguez-Grau, Maria] Hosp Univ Henares, Gastroenterol Dept, Coslada 28002, Spain, [Plaza, Rocio] Hosp Univ Infanta Leonor, Gastroenterol Dept, Madrid 28031, Spain, [Perez-Galindo, Pablo] Complejo Hosp Univ Pontevedra, Gastroenterol Dept, Pontevedra 36071, Spain, [Martinez-Cadilla, Jesus] Hosp Alvaro Cunqueiro Vigo, Gastroenterol Dept, Vigo 36312, Spain, and Spanish Working Group in Crohn's Disease and Ulcerative Colitis (GETECCU)

Subjects
Gastroenterología y hepatología, Crohn’s disease, vedolizumab, medicine.medical_specialty, Crohns-disease, Cirurgia - Complicacions, Surgical complications, Productes biològics, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES], Outcomes, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Postoperative Complications [DISEASES], Crohn, Malaltia de, Lower risk, Inflammatory bowel disease, Article, ustekinumab, Vedolizumab, surgery, inflammatory bowel disease, Internal medicine, Ustekinumab, postoperative complications, Medicine, Risk factor, ulcerative colitis, Crohn's disease, preoperative therapy, business.industry, Postoperative infectious complications, Retrospective cohort study, General Medicine, anti-TNF, Metaanalysis, medicine.disease, Resection, mezclas complejas::productos biológicos [COMPUESTOS QUÍMICOS Y DROGAS], Ulcerative colitis, afecciones patológicas, signos y síntomas::procesos patológicos::complicaciones posoperatorias [ENFERMEDADES], Gastrointestinal surgery, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES], Risk-factors, Ulcerative-colitis, Preoperative steroid use, Complex Mixtures::Biological Products [CHEMICALS AND DRUGS], business, medicine.drug
Abstract

Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered “exposed”. The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5, 95% CI: 1.2–2.0), urgent surgery (OR: 1.6, 95% CI: 1.2–2.2), laparotomy approach (OR: 1.5, 95% CI: 1.1–1.9) and severe anaemia (OR: 1.8, 95% CI: 1.3–2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2, 95% CI: 0.97–1.58), although it could be a risk factor for postoperative infections (OR 1.5, 95% CI: 1.03–2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.

Published
2021

11. Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

Author

Casbas A, Zapater P, Ricart E, Gonzalez-Vivo M, Gordillo J, Olivares D, Vera-Mendoza I, Manosa M, Gisbert J, Aguas M, Sanchez-Rodriguez E, Bosca M, Laredo V, Camps B, Marin-Jimenez I, Zabana Y, Martin-Arranz M, Munoz R, Navarro-Llavat M, Sierra E, Madero L, Vela M, Perez-Calle J, Sainz E, Calvet X, Sicilia B, Morales V, Bermejo F, Fernandez-Salazar L, Van Domselaar M, De Castro L, Rodriguez C, Munoz-Villafranca C, Lorente R, Rivero M, Iglesias E, Herreros B, Barreiro-de-Acosta M, Domenech E, Frances R, and EIIMIGRA

Published
2021

12. Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience

Author

Barreiro-de Acosta M, Gutierrez A, Zabana Y, Beltran B, Calvet X, Chaparro M, Domenech E, Esteve M, Panes J, Gisbert J, Nos P, and GETECCU

Subjects
inflammatory bowel disease, quality of care, unit, standards, quality indicators, digestive system diseases
Abstract

Background One of the most valued targets in inflammatory bowel disease (IBD) is for physicians to provide and patients to receive a high-level quality of care. This study aimed to evaluate the implementation of a nationwide quality certification programme for IBD units. Methods Identification of quality indicators (QI) for IBD Unit certification was based on Delphi methodology that selected 53 QI, which were subjected to a normalisation process. Selected QI were then used in the certification process. Coordinated by GETECCU, this process began with a consulting round and an audit drill followed by a formal audit carried out by an independent certifying agency. This audit involved the scrutiny of the selected QI in medical records. If 80%-90% compliance was achieved, the IBD unit audited received the qualification of "advanced", and if it exceeded 90% the rating was "excellence". Afterwards, an anonymous survey was conducted among certified units to assess satisfaction with the programme for IBD units. Results As of January 2021, 66 IBD units adhere to the nationwide certification programme. Among the 53 units already audited by January 2021, 31 achieved the certification of excellence, 20 the advanced certification, and two did not obtain the certification. The main survey results indicated high satisfaction with an average score of 8.5 out of 10. Conclusion Certification of inflammatory bowel disease units by GETECCU is the largest nationwide certification programme for IBD units reported. More than 90% of IBD units adhered to the programme achieved the certification.

Published
2021

15. Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU

Author

Gisnsero F, Zabana Y, Fernandez-Cloret A, Sola A, Caballol B, Leo E, Garcia M, Bertoletti F, Alejandro M, Suris G, Casis B, Ferreiro-Iglesias R, Calafat M, Jimenez I, Miranda-Bautista J, Lamuela L, Fajardo I, Torrealba L, Najera R, Saiz R, Gonzalez I, Vicuna N, Garcia-Morales N, Gutierrez A, Lopez-Garcia A, Benitez J, de Celix C, Tejido C, Brunet E, Baston I, Rodriguez-Lago I, Baltar R, Huguet J, Hermida B, Caballero-Mateos A, Sanchez-Guillen L, Bouhmidi A, Pajares B, Lopez-Sanroman A, and Barreiro-de Acosta M

Published
2021

17. Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

Author

Hernández Camba A, Ramos L, Madrid Álvarez MB, Pérez-Méndez L, Nos P, Hernández V, Guerra I, Jiménez N, Lorente R, Sierra-Ausín M, Ginard D, Varela Trastoy P, Arranz L, Cabello Tapia MJ, Zabana Y, Barreiro-de Acosta M, and GETECCU

Subjects
Pandemia, Pandemic, Depression, IBD, COVID-19, Anxiety, Stress, digestive system diseases, Ansiedad, Confinamiento, Depresión, Lockdown, EII, DASS-21, Estrés
Abstract

OBJECTIVES: This multicenter cross-sectional study was conducted to assess the psychosocial impact of COVID-19 on patients with inflammatory bowel disease (IBD) in Spain during lockdown and the first wave of the pandemic. PATIENTS AND METHODS: A self-report questionnaire that integrated the Spanish version of the Depression, Anxiety and Stress Scale-21 items (DASS-21) and the Perceived Stress Questionnaire (PSS) was designed to gather sociodemographic data and information related to the effects of lockdown on the lives of IBD patients. Twelve IBD units invited their patients to answer the anonymous online survey between the 1st July and the 25th August 2020. RESULTS: Of the 693 survey participants with IBD, 67% were women and the mean age was 43 (SD 12). Sixty-one percent had ulcerative colitis, 36% Crohn's disease and 3% indeterminate colitis. DASS-21 scores indicate that during lockdown the estimated prevalence of depression was 11% [95% CI 8.2-13%], anxiety 20% [95% CI 17 to 23%] and stress 18% [95% CI 8.2-13%]. Multivariate analysis showed that the perceived high risk of COVID-19 infection because of having IBD and maladaptation to government measures to reduce the spread of disease doubled the risk of anxiety and stress during lockdown. CONCLUSIONS: In the short-term, lockdown during the COVID-19 pandemic seemed to have an impact on the already affected mental health of our IBD patients in Spain.

Published
2021

18. Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

Author

Gutierrez Casbas, A., Zapater, P., Ricart, E., Gonzalez-Vivo, M., Gordillo, J., Olivares, D., Vera-Mendoza, I., Manosa, M., Gisbert, J. P., Aguas, M., Sanchez-Rodriguez, E., Bosca, M., Laredo, V., Camps, B., Marin-Jimenez, I., Zabana, Y., Martin-Arranz, M. D., Munoz, R., Navarro-Llavat, M., Sierra, E., Madero, L., Vela, M., Perez-Calle, J., Sainz, E., Calvet, X., Sicilia, B., Morales, V., Bermejo, F., Luis Fernández-Salazar, Domselaar, M., Castro, L., Rodriguez, C., Munoz-Villafranca, C., Lorente, R., Rivero, M., Iglesias, E., Herreros, B., Barreiro-De-Acosta, M., Domenech, E., and Frances, R.

Published
2021

19. Use of capsule endoscopy in inflammatory bowel disease in clinical practice in Spain. Results from a national survey

Author

Elosua González A, Nantes Castillejo Ó, Fernández-Urién Sainz I, López-García A, Murcia Pomares Ó, Zabana Y, and en nombre de Grupo Joven GETECCU y del Grupo Joven de AEG

Subjects
Enfermedad inflamatoria intestinal, Cápsula endoscópica, Capsule endoscopy, Inflammatory bowel disease
Abstract

INTRODUCTION: Small bowel capsule endoscopy (SBCE) is a non-invasive diagnostic technique whose use in inflammatory bowel disease (IBD) has spread. A panenteric capsule, PillCam Crohn's (PCC), has recently been developed. We lack information on the availability and use of the CEID and PCC in our environment. METHODS: We conducted an electronic and anonymous survey among the members of the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) [Spanish Working Group on Crohn's Disease and Ulcerative Colitis] and the Asociación Española de Gastroenterología (AEG) [Spanish Association of Gastroenterology], consisting of 37 multiple-choice questions. RESULTS: One hundred and fifty members participated, the majority dedicated to IBD (69.3%). 72.8% worked at centres with an IBD unit. 79% had SBCE available at their hospital, 14% referred patients to another centre; 22% had a PCC available, 9% referred patients to another centre. 79.3% of respondents with available SBCE used it in a small percentage of patients with IBD and 15.6% in the majority. The most frequent scenarios were suspicion of Crohn's disease (76.3%), assessment of inflammatory activity (54.7%) and assessment of the extent of the disease (54.7%). More than half (59.7%) preferentially used the Patency capsule to assess intestinal patency. Almost all respondents (99.3%) considered that training resources should be implemented in this technique. CONCLUSIONS: SBCE is widely available in Spanish hospitals for the management of IBD, although its use is still limited. There is an opportunity to increase training in this technique, and consequently its use.

Published
2021

20. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients

Author

Sicilia B, Vicente R, Arias L, Echarri A, Zabana Y, Mañosa M, Beltrán B, and Barreiro-de Acosta M

Subjects
Crohn's disease, Dysplasia, Ulcerative colitis, Crohn’s disease, chromoendoscopy, colitis ulcerosa, cromoendoscopia, displasia, dysplasia, enfermedad de Crohn, enfermedad inflamatoria intestinal, inflammatory bowel disease, ulcerative colitis, Chromoendoscopy, Inflammatory bowel disease
Abstract

Colonic inflammatory bowel diseases have a higher risk of developing colorectal cancer compared to the general population, which is why they require endoscopic screening techniques with specific follow-up intervals based on the different risk factors described on the literature. This position paper analyzes the current scientific evidence for the different endoscopic techniques available today, how their implementation should be carried out in endoscopic units and describes in detail how their implementation should be carried out, in which patients and with what interval, and finally, what should be the response to finding dysplasia, proposing a specific follow-up algorithm. (C) 2021 The Author(s). Published by Elsevier Espana, S.L.U.

Published
2021

21. Impact of biological agents on postoperative complications in inflammatory bowel disease: a multicentre study of GETECCU

Author

Garcia M, Rivero M, Miranda-Bautista J, Baston-Rey I, Mesonero E, Leo-Carnerero E, Casas-Deza D, Fernandez C, Martin-Cardona A, El Hajra I, Hernandez-Aretxabaleta N, Perez-Martinez I, Fuentes-Valenzuela E, Jimenez N, de Celix C, Gutierrez A, Ferrer C, Huguer J, Fernandez-Cloter A, Gonzalez-Vivo M, Del Val B, Castro-Poceiro J, Melcarne L, Duenas C, Izquierdo M, Monfort D, Bouhmidi A, De la Piscina P, Romero E, Molina G, Zorrilla J, Calvino-Suarez C, Sanchez E, Nunez A, Sierra O, Castro B, Zabana Y, Gonzalez-Partida I, Chaparro M, and Gisbert J

Published
2021

23. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Kucharzik, T, Ellul, P, Greuter, T, Rahier, Jean-François, Verstockt, B, Abreu, C, Albuquerque, A, Alloca, M, Esteve, M, Farraye, F A, Gordon, H, Karmiris, K, Kopylov, U, Kirchgesner, J, MacMahon, E, Magro, F, Maaser, C, de Ridder, L, Taxonera, C, Toruner, M, Tremblay, L, Scharl, M, Viget, N, Zabana, Y, Vavricka, S, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Kucharzik, T, Ellul, P, Greuter, T, Rahier, Jean-François, Verstockt, B, Abreu, C, Albuquerque, A, Alloca, M, Esteve, M, Farraye, F A, Gordon, H, Karmiris, K, Kopylov, U, Kirchgesner, J, MacMahon, E, Magro, F, Maaser, C, de Ridder, L, Taxonera, C, Toruner, M, Tremblay, L, Scharl, M, Viget, N, Zabana, Y, and Vavricka, S

Published
2021

24. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

Author

Andujar, X, Loras, C, Gonzalez, B, Socarras, M, Sanchiz, V, Bosca, M, Domenech, E, Calafat, M, Rodriguez, E, Sicilia, B, Calvet, X, Barrio, J, Guardiola, J, Iglesias, E, Casanova, MJ, Ber, Y, Monfort, D, Lopez-Sanroman, A, Rodriguez-Lago, I, Bujanda, L, Marquez, L, Martin-Arranz, MD, Zabana, Y, Fernandez-Banares, F, Esteve, M, Panes, J, Minguez, M, Sanchez, VG, Perez-Gisbert, J, Gomollon, F, Piqueras, M, Cabriada, JL, and Andreu, M

Subjects
Crohn's disease, Endoscopic balloon dilation, Inflammatory bowel disease
Abstract

Background There is no information regarding the outcome of Crohn's disease (CD) patients treated with endoscopic balloon dilation (EBD) in non-referral hospitals, nor on the efficacy of EBD in ulcerative colitis (UC). We report herein the results of the largest series published to date. Aim To assess the efficacy and safety of EBD for inflammatory bowel disease (IBD) stenosis performed in 19 hospitals with different levels of complexity and to determine factors related to therapeutic success. Methods We identified IBD patients undergoing EBD in the ENEIDA database. Efficacy of EBD was compared between CD and UC and between secondary and tertiary hospitals. Predictive factors of therapeutic success were assessed with multivariate analysis. Results Four-hundred dilations (41.2% anastomotic) were performed in 187 IBD patients (13 UC/Indeterminate colitis). Technical and therapeutic success per dilation was achieved in 79.5% and 55.3%, respectively. Therapeutic success per patient was achieved in 78.1% of cases (median follow-up: 40 months) with 49.7% requiring more than one dilation. No differences related to either diagnosis or hospital complexity was found. Technical success [OR 4.12 (95%CI 2.4-7.1)] and not receiving anti-TNF at the time of dilation [OR 1.7 (95% CI 1.1-2.6)] were independently related to therapeutic success per dilation. A stricture length

Published
2020

25. El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes genéticos y Ambientales) de GETECCU: diseño, monitorización y funciones

Author

Zabana, Y., Panés, J., Nos, P., Gomollón, Fernando, Esteve, M., García-Sánchez, V., Gisbert, J.P., Barreiro-de-Acosta, M., Domènech, E., en representacion de GETECCU, UAM. Departamento de Medicina, and Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP)

Subjects
Hepatology, business.industry, Medicina, Gastroenterology, Inflammatory bowel diseases, Malalties inflamatòries intestinals, 03 medical and health sciences, Crohn's disease, 0302 clinical medicine, ENEIDA, Malaltia de Crohn, Ulcerative colitis, Colitis ulcerosa, Enfermedad inflamatoria intestinal, 030220 oncology & carcinogenesis, GETECCU, Medicine, 030211 gastroenterology & hepatology, Registro, business, Humanities
Abstract

El registro ENEIDA, promovido por el Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU), fue creado en 2005 por un grupo de gastroenterólogos interesados en mejorar el manejo de los pacientes con enfermedad inflamatoria intestinal. Los objetivos principales del registro fueron facilitar la recogida de datos clínicos de interés para la práctica clínica asistencial, así como la elaboración de estudios colaborativos a partir de datos clínicos y muestras biológicas. En sus 15 años de existencia, ENEIDA ha evolucionado en múltiples aspectos, desde su contenido o su soporte tecnológico hasta el número de centros participantes, para convertirse en uno de los registros de referencia para el estudio y cuidado de los pacientes con enfermedad inflamatoria intestinal, con una producción científica continua y de alta calidad que lo ha situado como ejemplo de explotación científica colaborativa en el ámbito internacional. En este artículo se revisan los objetivos, el diseño, las características estructurales, la monitorización y la explotación científica del registro ENEIDA, The ENEIDA registry, promoted by the Spanish Working Group on Crohn’s Disease andUlcerative Colitis (GETECCU), was created in 2005 by a group of gastroenterologists interested inimproving the management of patients with inflammatory bowel disease. The main objectives ofthe registry were to facilitate the collection of clinical data of interest for clinical care practice,as well as to carry out collaborative studies using clinical data and biological samples. In its15 years of existence, ENEIDA has evolved in many aspects, from its content or technologicalsupport to the number of participating centres, to become one of the reference registries forthe study and care of patients with inflammatory bowel disease, with a continuous and highquality scientific production that has positioned it as an example of collaborative scientificexploitation at an international level. This article reviews the objectives, design, structuralcharacteristics, monitoring and scientific exploitation of the ENEIDA registry.

Published
2020

26. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry (vol 34, pg 1112, 2020)

Author

And?jar X, Loras C, Gonz?lez B, Socarras M, Sanchiz V, Bosc? M, Domenech E, Calafat M, Rodr?guez E, Sicilia B, Calvet X, Barrio J, Guardiola J, Iglesias E, Casanova M, Ber Y, Monfort D, L?pez-Sanroman A, Rodr?guez-Lago I, Bujanda L, M?rquez L, Mart?n-Arranz M, Zabana Y, Fernandez-Ba?ares F, Esteve M, and ENEIDA Registry GETECCU

Abstract

Javier P. Gisbert was listed incorrectly as Javier Perez-Gisbert.

Published
2020

29. Increased risk of thiopurine-related adverse events in elderly patients with IBD

Author

Calafat, M, Maosa, M, Caete, F, Ricart, E, Iglesias, E, Calvo, M, Rodrguez-Moranta, F, Taxonera, C, Nos, P, Mesonero, F, Martn-Arranz, MD, Mnguez, M, Gisbert, JP, Garca-Lpez, S, de Francisco, R, Gomolln, F, Calvet, X, Garcia-Planella, E, Rivero, M, Martnez-Cadilla, J, Argelles, F, Arias, L, Cimavilla, M, Zabana, Y, Domnech, E, Abad, A, Alcain, G, Almela, P, Barreiro-de-Acosta, M, Ber, Y, Bermejo, F, Bujanda, L, Busquets, D, Charro, M, Garca-Bosch, O, Garca-Sepulcre, MF, Gutirrez, A, Khorrami, S, Lzaro, J, Legido, J, Lia, J, Lucendo, AJ, Madrigal, RE, Mrquez, L, Martnez-Montiel, P, Merino, O, Monfort, D, Mora, M, Muoz-Villafranca, C, Ramos, L, Riera, J, Prez, AR, Gutirrez, CR, Rodrguez-Pescador, A, Romero, P, Roncero, O, Ses, E, Trapero, AM, Van Domselaar, M, Vela, M, Velayos, B, Verdejo, C, and Huguet, JM

Abstract

Background Thiopurines are the most widely used immunosuppressants in IBD although drug-related adverse events (AE) occur in 20%-30% of cases. Aim To evaluate the safety of thiopurines in elderly IBD patients Methods Cohort study including all adult patients in the ENEIDA registry who received thiopurines. Patients were grouped in terms of age at the beginning of thiopurine treatment, specifically in those who started thiopurines over 60 years or between 18 and 50 years of age. Thiopurine-related AEs registered in the ENEIDA database were compared. Results Out of 48 752 patients, 1888 thiopurines when over 60 years of age and 15 477 under 50 years of age. Median treatment duration was significantly shorter for those who started thiopurines >60 years (13 [IQR 2-55] vs 32 [IQR 5-82] months; P < .001). Patients starting >60 years had higher rates of all types of myelotoxicity, digestive intolerance and hepatotoxicity. Thiopurines were discontinued due to AEs (excluding malignancies and infections) in more patients starting >60 years (67.2% vs 63.1%; P < .001). Elderly age and female sex were independent risk factors for most AEs. Conclusion In elderly IBD patients, thiopurines are associated with an increased risk of non-infectious, non-neoplastic, AEs.

Published
2019

30. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers

Author

Manosa, M, Chaparro, M, Juan, A, Arajol, C, Alfaro, I, Minguez, M, Velayos, B, Benitez, JM, Mesonero, F, Sicilia, B, Zabana, Y, Villoria, A, Gisbert, JP, and Domenech, E

Abstract

OBJECTIVES:Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate the spread and recurrence of cancer. This study assesses the impact of the use of IMTs on the development of incident cancers (recurrent or new) in patients with inflammatory bowel disease (IBD) and a history of malignancy.METHODS:Patients with IBD included in the ENEIDA registry with a history of cancer without being exposed to IMTs were identified and retrospectively reviewed and compared regarding further treatment with IMTs or not by means of a log-rank test.RESULTS:Overall, 520 patients with previous extracolonic cancer naive to IMTs before the diagnosis of cancer were identified. Of these, 146 were subsequently treated with IMTs (exposed), whereas 374 were not (nonexposed). The proportion of patients with incident cancers was similar in both exposed (16%) and nonexposed (18%) patients (P = 0.53); however, there was more than a 10-year difference in the age at index cancer between these 2 groups. Cancer-free survival was 99%, 98%, and 97% at 1, 2, and 5 years in exposed patients, and 97%, 96%, and 92% at 1, 2, and 5 years in non-exposed patients, respectively (P = 0.03). No differences in incident cancer rates were observed between exposed and nonexposed patients when including only those who were exposed within the first 5 years after cancer diagnosis.DISCUSSION:In patients with IBD and a history of cancer not related to immunosuppression, the use of IMTs is not associated with an increased risk of new or recurrent cancers even when IMTs are started early after cancer diagnosis.

Published
2019

31. Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

Author

Sainz Arnau, E., Zabana, Y., Miguel, I., Fernandez Clotet, A., Casanova, M. J., Martin, M. D., Pico, M. D., Alfambra, E., Rodriguez, I., Munoz, F., Dominguez, M., Iglesias, E., Busquets, D., Gutierrez, A., Canete, F., Nunez, L., Taxonera, C., Beltran, B., Camps, B., Calvet, X., Navarro, P., Calafat, M., Ferreiro-Iglesias, R., Gonzalez-Munoza, C., Sicilia, B., Rodriguez, C., Carbajo, A. Y., Domselaar, M., Vicente, R., Piqueras, M., Munoz, M. C., Abad, A., Algaba, A., Martinez, P., Vela, M. I., Antolin, B., Huguet, J. M., Luis Bujanda, Lorente, R. H., Almela, P., Garcia, M. J., Ramirez La Piscina, P., Pajares, R., Perez-Martinez, I., Lucendo, A. J., Merino, O., Legido, J., Vera, I., Morales, V. J., and Esteve, M.

Published
2019

33. Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry

Author

Calafat, M, Manosa, M, Ricart, E, Iglesias, E, Calvo, M, Rodriguez-Moranta, F, Taxonera, C, Nos, P, Mesonero, F, Martin-Arranz, M, Minguez, M, Gisbert, JP, Garcia-Lopez, S, de Francisco, R, Gomollon, F, Calvet, X, Garcia-Planella, E, Rivero, M, Martinez-Cadila, J, Arguelles, F, Arias, L, Cimavilla, M, Zabana, Y, Canete, F, Cabre, E, and Domenech, E

Published
2019

34. Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Author

Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty GA, Fernandez-Salazar L, Martínez Cadilla J, Huguet JM, O'Toole A, Stasi E, Manceñido Marcos N, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, Martín-de-Carpi J, and Gisbert JP

Abstract

OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.

Published
2018

35. Prevalence and risk factors for colorectal adenomas in patients with ulcerative colitis

Author

Gordillo, J, Zabana, Y, Garcia-Planella, E, Manosa, M, Llao, J, Gich, I, Marin, L, Szafranska, J, Sainz, S, Bessa, X, Cabre, E, and Domenech, E

Subjects
colorectal adenoma, metachronous lesion, Ulcerative colitis, risk factors, colorectal cancer
Abstract

Background: Patients with ulcerative colitis (UC) have an increased risk of colorectal cancer. Scarce data regarding the development of adenomas in these patients are available both for normal and colitic mucosa. Objective: The objective of this article is to evaluate the prevalence of adenomatous polyps and associated risk factors in patients with UC. Methods: Patients with UC were identified from the databases of two tertiary referral centers. Medical, endoscopic and histologic reports were reviewed. Results: A total of 403 patients were included (53% male; 33% extensive colitis) and 1065 colonoscopies (median per patient, 2) were recorded and analyzed. Seventy-four adenomas in 47 patients (11.7%) and three cases of colorectal cancer were found during a median follow-up of 6.3 years. The cumulative risk of colorectal adenoma was 4.7%, 16.7%, 23.6% and 34.4% at 10, 20, 30 and 40 years from UC diagnosis, respectively. The cumulative risk of developing metachronous colorectal adenoma was 66.7%, 87.9%, and 90.9% at 5, 10, and 15 years from first adenoma detection. Older age at UC diagnosis and longer disease duration were independent risk factors for colorectal adenoma development. Conclusions: The prevalence of colorectal adenomas among UC patients seems to be higher than previously reported, although lower than in the background population.

Published
2018

36. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients

Author

Barreiro-de Acosta, M, Marin-Jimenez, I, Panadero, A, Guardiola, J, Cañas M, Gobbo Montoya M, Modino, Y, Alcain, G, Bosca-Watts, MM, Calvet, X, Casellas, F, Chaparro, M, Fernández Salazar L, Ferreiro-Iglesias, R, Ginard, D, Iborra, M, Manceñido N, Mañosa M, Merino, O, Rivero, M, Roncero, O, Sempere, L, Vega, P, Zabana, Y, Minguez, M, Nos, P, and Gisbert, JP

Subjects
Crohn's disease, Psychological problems, Ulcerative colitis, Depression, Anxiety, Clinical practice guidelines, Inflammatory bowel disease
Abstract

Aims: To establish recommendations for the management of psychological problems affecting patients with inflammatory bowel disease (IBD). Methods: A meeting of a group of IBD experts made up of doctors, psychologists, nurses and patient representatives was held. The following were presented: 1) Results of a previous focal group, 2) Results of doctor and patient surveys, 3) Results of a systematic review of tools for detecting anxiety and depression. A guided discussion was then held about the most important psychological and emotional problems associated with IBD, appropriate referral criteria and situations to be avoided. The validated instrument most applicable to clinical practice was selected. A recommendations document and a Delphi survey were designed. The survey was sent to the group and to a scientific committee of the GETECCU group in order to establish the level of agreement with these recommendations. Results: Fifteen recommendations were established linked to 3 key processes: 1) What steps should be taken to identify psychological problems at an IBD appointment; 2) What are the criteria for referring patients to a mental health specialist; 3) How to approach psychological problems. Conclusions: Resources should be made available to healthcare professionals so that they can treat these problems during consultations, identify the disorders which could affect the clinical course of the disease and determine their impact on the patient's life in order that these can be treated and followed up by the most suitable professional. These recommendations could serve as a basis for redesigning IBD services or processes and as justification for the training of healthcare personnel. (C) 2017 Elsevier Espana, S.L.U. All rights reserved.

Published
2018

37. Phenotypic characteristics and use of therapeutic resources in elderly-onset inflammatory bowel disease: A multicentre, case control study

Author

Manosa, M., Calafat, M., de Francisco, R., GARCIA, C., Casanova, M. J., Huelin, P., Zabana, Y., Calvo, M., Minguez, M., Ruiz, A., Bastida, G., Hinojosa, J., Marquez, L., Barreiro-de-Acosta, M., Calvet, X., Monfort, D., Gomez, R., Rodriguez, E., Huguet, J. M., Rojas, M., Hervas, D., Atienza, R., Busquets, D., Zapata, E., Duenas, C., Charro, M., Martinez-Cerezo, F. J., Plaza, R., Vazquez, J. M., Gisbert, J. P., Cabre, E., and Domenech, E.

Published
2014

38. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)

Author

Loras C, Gisbert JP, Saro MC, Piqueras M, Sanchez-Montes C, Barrio J, Ordas I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernandez-Banares F, and Esteve M

Subjects
Hepatitis B vaccination, Anti-TNF treatment, virus diseases, Hepatitis B, Hepatitis C, digestive system diseases, Inflammatory bowel disease
Abstract

Aims: Assess IBD patients starting anti-TNF for the impact of preventive measures in HBV and/or HCV, and the predictive response factors to HBV vaccination. Methods: Multicenter prospective study including 389 IBD patients. Four interventions were established: I-1) anti-HBs 100 IU/L); I-2) anti-HBs >100 1U/L (previous effective vaccination): monitoring levels; I-3) anti-HBc and/or HCV+: analysis every two months; 1-4) HBsAg +: start anti-virals. Results: I-1 and I-2) For first vaccination, effective vaccination and seroprotection were obtained in 26.4% and 43.5%, and for revaccination 31.3% and 44.4%, respectively. Predictive factors of effective vaccination were age 30 years (OR = 2.2) and being vaccinated simultaneously with anti-TNF (OR = 5.2) instead of late vaccination, whereas age 30 years (OR = 2.6) and anti-TNF monotherapy (OR = 2.4) were predictive for seroprotection. 80.8% of patients previously vaccinated maintained titres at 29 months follow-up. The only factor related to maintaining titres was previous vaccination versus achieving effective vaccination during anti-TNF (HR = 2.49); I-3 and 1-4) HBV-DNA + without reactivation was detected in 7% of 29 anti-HBc. No reactivation was found in the remaining HCV (n = 5) or HBsAg (n = 4) patients. Conclusions: 1) Response to vaccination/revaccination is low in patients with anti-TNF. Young patients vaccinated at the beginning of anti-TNF and receiving it as a monotheraphy showed better response. 2) Long-lasting effective vaccination is greatest in patients previously vaccinated. 3) Following-up the established surveillance and/or preventive anti-viral therapy seems to be safe in HBV and HCV patients. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Published
2014

39. Sexual function and patients' perceptions in inflammatory bowel disease: a case-control survey

Author

Marin, L, Manosa, M, Garcia-Planella, E, Gordillo, J, Zabana, Y, Cabre, E, and Domenech, E

Subjects
Intercourse, Crohn's disease, Ulcerative colitis, Sexual function, Intimacy, Inflammatory bowel disease
Abstract

Sexuality is important when assessing quality of life (QoL), which is often disturbed in inflammatory bowel disease (IBD). However, sexuality is not addressed in most QoL questionnaires. To evaluate the prevalence and predisposing factors of sexual dysfunction among IBD patients, and their own perception. A postal survey was conducted in IBD patients 25-65 years of age from two tertiary centres. Patients were asked to provide a control of the same gender and age without IBD. The questionnaire assessed patient perception of the impact of IBD on their sexuality, and also allowed calculation of the Erectile Function International Index or the Female Sexual Function Index. A total of 355 patients and 200 controls were available for the final analysis. Both groups were comparable except for a higher proportion of individuals who had been treated for depression among patients. Half of the female and one-third of the male patients considered that both sexual desire and satisfaction worsened after IBD diagnosis. As compared to controls, both men and women with IBD showed significantly lower scores in sexual function indexes, but a higher prevalence of sexual dysfunction was only noticed among women. Independent predictors of sexual dysfunction among IBD patients were the use of corticosteroids in women, and the use of biological agents, depression and diabetes in men. Sexuality is often disturbed in IBD patients, particularly among women. Many factors seem to contribute to worsened intimacy. Sexuality should be considered when QoL is assessed in these patients.

Published
2013

40. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

Author

Rahier, JF, Ben-Horin, S, Chowers, Y, Conlon, C, De Munter, P, D'Haens, G, Domènech, E, Eliakim, R, Eser, A, Frater, J, Gassull, M, Giladi, M, Kaser, A, Lémann, M, Moreels, T, Moschen, A, Pollok, R, Reinisch, W, Schunter, M, Stange, EF, Tilg, H, Van Assche, G, Viget, N, Vucelic, B, Walsh, A, Weiss, G, Yazdanpanah, Y, Zabana, Y, Travis, SP, and Colombel, JF

Subjects
Prevention, Vaccination, parasitic diseases, Gastroenterology, Opportunistic infections, General Medicine, Human medicine, inflammatory bowel disease, opportunistic infections, prevention, vaccination, consensus, diagnosis, management, IBD, Inflammatory bowel disease, digestive system diseases
Abstract

Consensus on the European level is brought in order to promote early prevention, diagnosis and optimal management of opportunistic infections in inflammatory bowel disease on behalf of the European Crohn's and Colitis Organisation (ECCO).

Published
2009

41. Clinical outcome of newly diagnosed Crohn’s disease: comparative, retrospective, study before and after infliximab availability

Author

DOMÈNECH, E., primary, ZABANA, Y., additional, GARCIA-PLANELLA, E., additional, LÓPEZ SAN ROMÁN, A., additional, NOS, P., additional, GINARD, D., additional, GORDILLO, J., additional, MARTÍNEZ-SILVA, F., additional, BELTRÁN, B., additional, MAÑOSA, M., additional, CABRÉ, E., additional, and GASSULL, M. A., additional

Published
2009
Full Text
View/download PDF

42. P120 IMPACT OF THE AVAILABILITY OF IMMUNEMODULATORS OR INFLIXIMAB ON THE TREATMENT AND DISEASE COURSE IN TWO HOSPITAL COHORTS OF NEWLY-DIAGNOSED CROHN'S DISEASE (CD) PATIENTS

Author

Domènech, E., primary, Zabana, Y., additional, Garcia-Planella, E., additional, López-San Román, A., additional, Nos, P., additional, Ginard, D., additional, Gordillo, J., additional, Martinez-Silva, F., additional, Beltran, B., additional, Mañosa, M., additional, Cabré, E., additional, and Gassull, M., additional

Published
2008
Full Text
View/download PDF

47. Extracolonic neoplasias in Inflammatory Bowel Disease patients: Data from the GETECCU ENEIDA registry

Author

Chaparro, M., Benitez-Cantero, J. M., Lopez-Garcia, A., Juan, A., Guardiola, J., Minguez, M., Calvet, X., Marquez, L., Fernandez-Salazar, L., Luis Bujanda, Lopez-San Roman, A., Zabana, Y., Lorente, R., Barrio, J., Hinojosa, M. D., Iborra, M., Dominguez-Cajal, M., Domselaar, M., Garcia-Sepulcre, M. F., Gomollon, F., Piqueras, M., Alcain, G., Ramas, M., Garcia-Sanchez, V., Panes, J., Domenech, E., and Gisbert, J. P.

48. The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case-control study of the ENEIDA registry

Author

Calafat, M., Manosa, M., Canete, F., Panes, J., Garcia Sanchez, V., Calvo, M., Rodriguez-Moranta, F., Taxonera, C., Nos, P., Lopez Sanroman, A., Martin Arranz, M. D., Minguez, M., Gisbert, J. P., Garcia-Lopez, S., Francisco, R., Gomollon, F., Calvet, X., Garcia-Planella, E., Rivero, M., Martinez-Cadilla, J., Arguelles, F., Arias Garcia, L., Cimavilla, M., Zabana, Y., Marquez, L., Gutierrez, A., Alcain, G., Martinez Montiel, P., Lazaro, J., Busquets, D., Garcia Sepulcre, M. F., Verdejo, C., Bermejo, F., Mora, M., Monfort, D., Romero, P., Velayos, B., Rodriguez, C., Rodriguez, A., Merino, O., Rodriguez-Pescador, A., Luis Bujanda, Ber, Y., Vela, M., Roncero, O., Huguet, J. M., Garcia-Bosch, O., Barreiro-De-Acosta, M., Madrigal, R. E., Ramos, L., Domselaar, M., Almela, P., Llao, J., Lucendo, A. J., Munoz Vilafranca, C., Abad, A., Charro, M., Legido, J., Riera, J., Khorrami, S., Sese, E., Trapero, A. M., and Domenech, E.

49. Long-term safety of in utero exposure to anti-TNF alpha drugs for the treatment of inflammatory bowel diseases (IBD): Interim results of the TEDDY study

Author

Chaparro, M., Magro, F., Savarino, E., Zabana, Y., Pugliese, D., Shitrit, A. Bar-Gil, Fernandes Samue, L., Lopez-Serrano, P., Casanova, M. J., Luis Fernández-Salazar, Gutierrez, A., Vicente, R., Gravito-Soares, E., Rodriguez, C., Sebkova, L., Lissner, D., Magarotto, A., Rodriguez-Lago, I., Huguet, J. M., Diz-Lois Palomares, M. T., Fiorino, G., Guerra, I., Mantzaris, G. J., Silva, M., Bartolo, O., Donday, M. G., Ramas, M., Martin Carpi, J., and Gisbert, J. P.

50. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

Author

Yamile, Zabana, Ignacio, Marín-Jiménez, Iago, Rodríguez-Lago, Isabel, Vera, María Dolores, Martín-Arranz, Iván, Guerra, Javier, P Gisbert, Francisco, Mesonero, Olga, Benítez, Carlos, Taxonera, Ángel, Ponferrada-Díaz, Marta, Piqueras, Alfredo, J Lucendo, Berta, Caballol, Míriam, Mañosa, Pilar, Martínez-Montiel, Maia, Bosca-Watts, Jordi, Gordillo, Luis, Bujanda, Noemí, Manceñido, Teresa, Martínez-Pérez, Alicia, López, Cristina, Rodríguez-Gutiérrez, Santiago, García-López, Pablo, Vega, Montserrat, Rivero, Luigi, Melcarne, María, Calvo, Marisa, Iborra, Manuel, Barreiro de Acosta, Beatriz, Sicilia, Jesús, Barrio, José Lázaro, Pérez Calle, David, Busquets, Isabel, Pérez-Martínez, Mercè, Navarro-Llavat, Vicent, Hernández, Federico, Argüelles-Arias, Fernando, Ramírez Esteso, Susana, Meijide, Laura, Ramos, Fernando, Gomollón, Fernando, Muñoz, Gerard, Suris, Jone, Ortiz de Zarate, José María, Huguet, Jordina, Llaó, Mariana Fe, García-Sepulcre, Mónica, Sierra, Miguel, Durà, Sandra, Estrecha, Ana, Fuentes Coronel, Esther, Hinojosa, Lorenzo, Olivan, Eva, Iglesias, Ana, Gutiérrez, Pilar, Varela, Núria, Rull, Pau, Gilabert, Alejandro, Hernández-Camba, Alicia, Brotons, Daniel, Ginard, Eva, Sesé, Daniel, Carpio, Montserrat, Aceituno, José Luis, Cabriada, Yago, González-Lama, Laura, Jiménez, María, Chaparro, Antonio, López-San Román, Cristina, Alba, Rocío, Plaza-Santos, Raquel, Mena, Sonsoles, Tamarit-Sebastián, Elena, Ricart, Margalida, Calafat, Sonsoles, Olivares, Pablo, Navarro, Federico, Bertoletti, Horacio, Alonso-Galán, Ramón, Pajares, Pablo, Olcina, Pamela, Manzano, Eugeni, Domènech, Maria, Esteve, On Behalf Of The Eneida Registry Of Geteccu, Universidad de Sevilla. Departamento de Medicina, Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), [Zabana Y] Hospital Universitari Mútua Terrassa, Terrassa, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. [Marín-Jiménez I] Hospital Gregorio Marañón, Madrid, Spain. [Rodríguez-Lago I] Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain. Biocruces Bizkaia Health Research Institute, Galdakao, Spain. [Vera I] Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Martín-Arranz MD] Hospital Universitario La Paz, Madrid, Spain. [Guerra I] Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPaz), Madrid, Spain. [Piqueras M, Mena R] Servei de Digestologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, and Consorci Sanitari de Terrassa

Subjects
COVID-19, SARS-CoV-2, inflammatory bowel disease, 5-aminosalicylates, immunosuppression, Immunosupressió, Factors de risc en les malalties, Risk factors in diseases, terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunosupresión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], General Medicine, Inflammatory bowel diseases, COVID-19 (Malaltia), enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades intestinales::enfermedad inflamatoria intestinal [ENFERMEDADES], Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Inflammatory bowel disease, Malalties inflamatòries intestinals, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Digestive System Diseases::Gastrointestinal Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [DISEASES], Intestins - Inflamació, Immunosuppression
Abstract

COVID-19; Immunosuppression; Inflammatory bowel disease COVID-19; Immunosupressió; Malaltia inflamatòria intestinal COVID-19; Inmunosupresión; Enfermedad inflamatoria intestinal (1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case−control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March−July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3−5.9), occupational risk (OR: 2.9; 95%CI: 1.8−4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2−2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09−0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results